vasopressin   Click here for help

GtoPdb Ligand ID: 2168

Abbreviated name: AVP
Synonyms: ADH | antidiuretic hormone | arginine vasopressin | argipressin
Approved drug
vasopressin is an approved drug (FDA (date of approval not specified))
Comment: The approved drug is administered as an injection, as indicated by the INN.

As with all large peptide molecules, there is some ambiguity in representations of the stereochemistry of vasopressin, therefore the chemical structure shown here may differ slightly from that shown on other resouces linked to from the table above.
Species: Human, Mouse, Rat
Click here for help
IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: vasopressin

2D Structure
Click here for help
Click here for structure editor
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES NC(=O)CC1NC(=O)C(CCC(=O)N)NC(=O)C(Cc2ccccc2)NC(=O)C(Cc2ccc(cc2)O)NC(=O)C(CSSCC(NC1=O)C(=O)N1CCCC1C(=O)NC(C(=O)NCC(=O)N)CCCN=C(N)N)N
Isomeric SMILES NC(=O)C[C@@H]1NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2ccc(cc2)O)NC(=O)[C@H](CSSC[C@H](NC1=O)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(=O)NCC(=O)N)CCCN=C(N)N)N
InChI InChI=1S/C46H65N15O12S2/c47-27-22-74-75-23-33(45(73)61-17-5-9-34(61)44(72)56-28(8-4-16-53-46(51)52)39(67)54-21-37(50)65)60-43(71)32(20-36(49)64)59-40(68)29(14-15-35(48)63)55-41(69)31(18-24-6-2-1-3-7-24)58-42(70)30(57-38(27)66)19-25-10-12-26(62)13-11-25/h1-3,6-7,10-13,27-34,62H,4-5,8-9,14-23,47H2,(H2,48,63)(H2,49,64)(H2,50,65)(H,54,67)(H,55,69)(H,56,72)(H,57,66)(H,58,70)(H,59,68)(H,60,71)(H4,51,52,53)/t27-,28-,29-,30-,31-,32-,33-,34-/m0/s1
InChI Key KBZOIRJILGZLEJ-LGYYRGKSSA-N
Natural/Endogenous Targets
Target
OT receptor
V1A receptor
V1B receptor
V2 receptor
Transporters Moving this Compound Across a Lipid Membrane
Transporter EC number Reaction Reference
OATP3A1
Selectivity at GPCRs
Key to terms and symbols Click column headers to sort
Target Sp. Type Action Value Parameter Concentration range (M) Reference
V1B receptor Ligand is endogenous in the given species Rn Agonist Full agonist 9.9 pKi - 15
pKi 9.9 [15]
V1B receptor Primary target of this compound Ligand is endogenous in the given species Hs Agonist Full agonist 9.0 – 9.5 pKi - 1,3,8-9,12,15,17-18,20-21
pKi 9.0 – 9.5 [1,3,8-9,12,15,17-18,20-21]
V1A receptor Primary target of this compound Ligand is endogenous in the given species Hs Agonist Full agonist 8.5 – 9.3 pKi - 1,3,7-8,12,14-15,17-21
pKi 8.5 – 9.3 [1,3,7-8,12,14-15,17-21]
V2 receptor Primary target of this compound Ligand is endogenous in the given species Hs Agonist Full agonist 7.9 – 9.1 pKi - 1,3-4,8,12,15-18,20-21
pKi 7.9 – 9.1 [1,3-4,8,12,15-18,20-21]
V1A receptor Ligand is endogenous in the given species Rn Agonist Full agonist 8.4 pKi - 4
pKi 8.4 [4]
OT receptor Ligand is endogenous in the given species Hs Agonist Partial agonist 7.3 – 9.3 pKi - 1-5,8-10
pKi 7.3 – 9.3 [1-5,8-10]
Additional information and targets (data relate to human unless otherwise stated)
Description Data Reference
Targets where the ligand is described in the comment field
Target Comment
Ligand mentioned in the following text fields